3

4 5

6 7

8 9 10

11

12

13

14

15

16 17

18

19

20

21

22 23

24

25

30

31

32

33

34

The effect of intimate partner violence on women's risk of HIV acquisition and engagement in the HIV treatment and care cascade: an individual-participant data meta-analysis of nationally representative surveys in sub-Saharan Africa Kuchukhidze S¹ MPH, Panagiotoglou D¹ PhD, Boily MC² PhD, Diabaté S^{3,4,5} MD, Eaton JW² PhD, Mbofana F⁶ MD, Sardinha L⁷ PhD, Schrubbe L⁸ MSc, Stöckl H⁹ PhD, Wanyenze RK¹⁰ PhD, and Maheu-Giroux M¹ ScD * **Affiliations** 1- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada 2- Medical Research Council (MRC) Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom 3- Département de médecine sociale et préventive, Université Laval, Québec, OC Canada 4- Centre de recherche du CHU de Québec, Université Laval, Québec, QC, Canada 5- Université Alassane Ouattara, Bouaké, Côte d'Ivoire 6- Conselho Nacional de Combate ao HIV/Sida, Maputo, Mozambique 7- School for Policy Studies, University of Bristol, Bristol, United Kingdom 8- Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK 9- Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany 10- Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda *Corresponding author Mathieu Maheu-Giroux 2001 Avenue McGill College, Suite 1200 Montréal, Québec H3A 1G1, CANADA mathieu.maheu-giroux@mcgill.ca

Abstract

Background:

Achieving the 95-95-95 targets for HIV diagnosis, treatment, and viral load suppression (VLS) to end the HIV/AIDS epidemic hinges on eliminating structural inequalities, including intimate partner violence (IPV). Sub-Saharan Africa (SSA) has among the world's highest prevalence of IPV and HIV. We aim to examine the impact of IPV on recent HIV infection and women's engagement in the HIV care cascade.

Methods:

We pooled individual-level data from nationally representative surveys with information on physical and/or sexual IPV and HIV in SSA (2000-2020). We used Poisson regressions with robust standard errors to estimate adjusted prevalence ratios (aPR) of past year experience of IPV on recent HIV infection (measured using recency assays), past-year HIV testing, antiretroviral therapy (ART) uptake, and VLS among ever-partnered (currently/formerly married or cohabitating) women. Models were adjusted for women's age, age at sexual debut, residence type, marital status, education, and the survey's identifier (proxy of country and year).

Findings:

Fifty-seven surveys were available from thirty countries, encompassing 280,259 (N_i) individuals.
One-fifth of women reported physical and/or sexual IPV in the past year. Six surveys had
information on recent HIV infection and seven had data on ART uptake and VLS. Women
experiencing past year IPV were 3·22 times (95%CI: 1·51-6·85, N_i=19,179) more likely to have
a recent HIV infection, adjusting for potential confounders. Past year IPV was not associated

a recent HIV infection, adjusting for potential confounders. Past year IPV was not associated with HIV testing (aPR=0.99, 95%CI: 0.98-1.01, N_i=274,506) or ART uptake (aPR=0.96,

95%CI:0·90-1·03, N_i=5,629). Women living with HIV (WLHIV) experiencing IPV in the past year were 9% less likely to achieve VLS (aPR=0·91, 95%CI: 0·85-0·98, N_i=5,627).

Interpretation:

- Past year IPV was associated with recent HIV acquisition and lower VLS among WLHIV.
- Preventing IPV is inherently imperative but eliminating IPV could also be crucial to ending HIV/AIDS.

Funding:

Canadian Institutes of Health Research, Canada Research Chair, and Max E. Binz Fellowship

Research in Context

Evidence before this study

Our study builds on more than two decades of research devoted to IPV and HIV.¹⁻⁴ We summarized this scholarship by searching PubMed for empirical studies (April 8, 2022), without language restrictions using the terms: HIV AND women AND (violence OR intimate partner OR domestic violence OR GBV OR IPV) AND (Africa* OR sub-Sahara*).

Several systematic and scoping reviews have been conducted on the links between IPV and HIV with mixed results.⁵⁻⁷ Most studies used HIV seropositivity as the outcome. In sub-Saharan Africa, a multi-country study found no association between IPV and HIV; however it has been subsequently suggested that women experiencing IPV have an increased risk of HIV seropositivity depending on the chosen referent group.⁸ Longitudinal studies in Uganda and South Africa suggest that women experiencing IPV are more likely to acquire HIV compared to those who are not.^{9,10} However, two other cohort studies among youth¹¹ and serodiscordant couples¹² did not find significant associations.

Impacts of IPV on the HIV prevention and treatment cascade have also been studied. A 2015 meta-analysis of 13 cross-sectional studies, mostly from the United States, found that IPV is associated with lower ART use, adherence and VLS. ¹³ For the first step in the cascade – HIV diagnosis – most included studies in a 2019 scoping review by Leddy ¹⁴ did not find an association between IPV and HIV testing ¹⁵⁻¹⁹; though two reported a reduction in testing associated with IPV among pregnant and postpartum women. ^{20,21}

Evidence supports a negative relationship between IPV and ART adherence, though most studies focused on populations such as sex workers¹⁷, youth²², or pregnant/postpartum women. ^{18,23-25} Quantitative evidence are sparse on ART *uptake*, but among five studies from high income settings, none showed an association between IPV and *current* ART use. ¹³ Studies from Zambia and South Africa point to an association between IPV and unsuppressed viral loads among adolescents/youth²⁶ and postpartum women. ²⁷

Overall, comparison of estimates and outcomes is difficult due to a lack of standardization in survey instruments, recall period for IPV, considered IPV types, outcome measurement, and populations considered (e.g., pregnant and/or young women, sex workers).

Added value of this study

Using microdata from population-based surveys in the region with the highest HIV burden, we conducted the largest and most comprehensive study to date on the impacts of IPV on HIV: from HIV acquisition to the three most important steps of the treatment and care cascade. Our results generally corroborate previous findings, but we considerably expanded the scope of previous studies using recent experiences of IPV, consideration of partner characteristics, and estimating their impact on biomarker-based measures of HIV acquisition, ART coverage, and VLS.

The implications of all the available evidence

The 2021 Political Declaration on AIDS commits to eliminating sexual and gender-based violence, including IPV as key to combatting the AIDS epidemic. IPV is an urgent public health concern, and a barrier to the elimination of AIDS. Our results highlight the need for HIV programs to consider IPV along the full continuum of HIV prevention to treatment and care. Both IPV and HIV are preventable. Governments, societies, and communities need to explicitly recognize the IPV-HIV syndemic, and implement multisectoral response with social and economic components to eliminate gender-based violence and end AIDS.

Introduction

Despite significant progress to curb HIV epidemics worldwide, 1.5 million new HIV infections occurred in 2020, over 60% of which were in sub-Saharan Africa.²⁸ This burden of new infections disproportionately affects women: they account for 65% of new HIV infections in sub-Saharan Africa. 28,29 The global HIV agenda is guided by the "95-95-95" targets to end AIDS by 2030 — an ambitious plan that calls for achieving 95% diagnosis coverage, 95% antiretroviral therapy (ART) uptake among those diagnosed, and 95% of viral suppression among those on treatement.³⁰ Reaching these targets partly hinges upon addressing structural vulnerabilities such as inequitable gender and social norms, and violence against women and girls. Worldwide, over one in four women has experienced physical and/or sexual intimate partner violence (IPV) in their lifetime, with prevalence reaching highs of approximately 40% in Central and Eastern sub-Saharan Africa.³¹ This violence often co-occurs with HIV and could function as a syndemic, posing barriers to women's ability to prevent HIV acquisition, to access HIV care, and to remain in care if living with the virus. The 2021 United Nations General Assembly adopted the Political Declaration on HIV and AIDS with bold new global targets for 2025, which commit to elimination of all forms of sexual and gender-based violence, including IPV as a key enabler of the HIV epidemic.³² Improving our understanding of the complex relationships between IPV and HIV is essential to meet this commitment.

In sub-Saharan Africa, women being subjected to IPV could be at increased risk of HIV acquisition. Selfont HIV incidence, IPV could compromise access to the HIV prevention and care cascade From HIV testing, to ART uptake and retention ART uptake and retention Id, IT, 22, 34, and ultimately, to viral load suppression (VLS). Selfont IRV evidence suggesting that IPV and HIV interact in a syndemic way could be strengthened. Previous studies either provided mixed results, focused on a single country, and/or recruited specific populations such as pregnant women, selfont youth youth

Our overarching aim was to improve understanding of the complex relationships between women's experience of IPV and HIV acquisition, and engagement with the HIV prevention and treatment cascade.^{2,3,33} To achieve this, we estimated the impact of recent (past 12 months) physical and/or sexual IPV on the following four outcomes: recent HIV infection, self-reported HIV testing in the past year, ART uptake, and VLS.

Methods

112

113

114

115

116

117

118 119

120

121

122

123

124

134

135

136

137

138

139

140

141

142

143

144

145 146

147

148

149

150

151

Data sources and study population

We reviewed all available nationally-representative, cross-sectional, population-based surveys from sub-Saharan Africa over 2000-2020 with individual participant data on both IPV and HIV. We searched data catalogs (i.e., the Global Health Data Exchange, the International Household Survey Network), examined surveys included in the Global Estimates for Violence Against Women Statistics systematic review³⁶, a previous review of surveys with information on HIV testing³⁷, and complemented these with expert knowledge.

The types of surveys considered included *Demographic and Health Surveys* (DHS), *AIDS* Indicator Surveys (AIS) (https://dhsprogram.com/Data/), Population-based HIV Impact Assessment (PHIA) (https://phia-data.icap.columbia.edu/datasets) and South Africa National HIV Prevalence, Incidence, Behavior and Communication Survey (SABSSM) (http://datacuration.hsrc.ac.za/search/browse/alpha/S), as well as country-specific surveys (e.g., Botswana AIDS Impact Survey, Kenya AIDS Indicator Surveys, and Nigeria HIV/AIDS Indicator

- 125 126 and Impact Survey). Study population included all ever-partnered (currently or formerly married
- 127 or cohabitating) women and girls aged ≥15 years (Figure 1).
- 128 Measurement of experience of IPV
- 129 In all surveys, data on IPV was collected from one randomly selected woman in each 130 household for PHIA and SABSSM, and from a fraction of households in DHS/AIS (usually one 131 third). The primary exposure of interest was experience of physical and/or sexual IPV in the past 132 year (Supplement 1; Table S1). All surveys used acts-specific, gold-standard instruments based on the modified Conflict Tactics Scale to collect information on IPV. 38,39 133
 - The secondary exposures of interest were a) lifetime experience of physical IPV only, b) lifetime experience of sexual IPV only, c) lifetime experience of physical and/or sexual IPV, d) lifetime experience of severe physical and/or sexual IPV, and d) frequent past year experience of physical and/or sexual IPV. Measurements are generally consistent across surveys, although PHIAs collected information on past year IPV only (no lifetime measure) (Supplement 1; Table S1) and in SABSSM, past year IPV pertains to physical violence only (i.e., no information on sexual violence).
 - Severity of lifetime IPV was collected only in the DHS and SABSSM (number of surveys, N_{surv}=52). Severe IPV was defined as lifetime experience of severe physical and/or sexual IPV, which includes punching, kicking/dragging, trying to strangle/burn, threatening with a weapon, attacking with a weapon, and any type of sexual IPV.⁴⁰ (Supplement 1; Table S1)

Frequency of past year physical and/or sexual IPV was categorized as "often", "sometimes", or "never". In PHIA, the frequency question pertains to the experience of physical violence by any perpetrator in the past year, and we assumed this to be an intimate partner only if the participant reported IPV as well (Supplement 1; Table S1). Further, in the SABSSM and PHIA surveys, the frequency of past year IPV pertains to only physical IPV while in other surveys the indicator refers to frequency of physical and/or sexual IPV. Whenever the survey did

not collect the information, we extrapolated the frequency of physical IPV to that of physical

and/or sexual IPV based on the strong relationship between both measures (X-squared = 43,780,

153 p<0.05).

Outcome measurements

Our primary outcome is recent HIV infection (as a proxy for HIV incidence) among women at risk of HIV acquisition (i.e., excluding those living with non-recent HIV). Recency was measured via LAg assay performed on all participants found to be seropositive for HIV. The algorithm to identify recent infections –those that were acquired less than four to seven months before sample collection ^{41,42} – accounted for ART biomarkers and VLS to minimize false positives. ⁴³

Other outcomes concern the HIV prevention and treatment cascade. (Supplement 1; Table S2) First, we considered self-reported HIV testing histories (lifetime and past year testing and receipt of result). Second, ART uptake was measured among ever-partnered women living with HIV (WLHIV) based on either ART biomarkers or self-reports of currently taking ART. Finally, WLHIV were considered virally suppressed if their HIV RNA viral load was <1000 copies/mL. Women with a recent HIV infection were excluded from the ART uptake and viral suppression analyses (Supplement 1; Table S2).

Statistical analyses

Individual-level data from each survey were pooled to calculate crude and adjusted prevalence ratios (PR) for the association between IPV and recent HIV infection, HIV testing, ART uptake and VLS. Adjusted prevalence ratios (aPR) were estimated accounting for potential confounders such as: women's age, residence type (rural/urban), women's marital status, women's education, and survey-level fixed effects (survey country and year). An additional adjustment variable for the HIV recency analysis was age at sexual debut. These confounders were available from all surveys and had been previously identified as being potentially linked to both IPV and the outcomes. 44-48 The survey-level fixed effects allowed us to control for any measured/unmeasured survey-level confounders.

Modified Poisson regression models were used to obtain the crude and adjusted PR based on Generalized Estimating Equations (GEE) with robust standard errors that accounted for the sampling design (i.e., exchangeable correlation structure with the primary sampling units as the clustering variable). Survey weights were not included in the regression^{8,49} as they are often unwarranted to obtain unbiased estimates. ⁵⁰ We used a complete case analysis since the proportion of missing observations was small for all outcomes ($\leq 4\%$). Supplemental materials include information on the missing observations and the analyses of potential biases (Supplement 2). The R software (4.0.0) and the 'geepack' package were used for all analyses. ⁵¹

Sensitivity analyses

In sensitivity analyses we examined the robustness of our results by only including women testing outside of the antenatal care (ANC) in the analyses of HIV testing to examine if IPV has a differential impact by testing modality. We restricted the analysis of VLS to women on ART (i.e., conditioning on achieving this step in the cascade). To investigate if partner or

couple's characteristics confound the relationship between IPV and HIV acquisition we linked data for married or cohabiting men and women who both declared to be co-habiting. We then calculated proportions of male partners living with HIV, male partner age, partner education, partner alcohol consumption, mean partner age discrepancy and condom use at women's most recent sex, stratified by experience of past year IPV.

All analyses were performed using secondary, de-identified data. DHS/AIS survey protocols are approved by the Internal Review Board of ICF International in Calverton (USA) and by the relevant country authorities for other surveys. Approval for data analyses was obtained from *McGill University's Faculty of Medicine and Health Sciences Institutional Review Board* (A12-B95-21B).

Role of the funding source

The funders had no role in the study's design, data analysis, interpretation, manuscript writing, and decision to publish.

Results

Description of included surveys

We identified 100 nationally representative surveys that included information on HIV testing (the most reported outcome), of which 64 were included in the HIV testing analysis and had data on IPV (51 DHS/AIS,5 PHIA,1 SABSSM) (Figure 1). After excluding 7 surveys, the resulting 57 surveys were conducted in 30 countries and included 280,259 unique female respondents aged 15-64 years (Supplement 3;Table S6). Women with missing data for all exposures of interest were excluded. Fifteen countries had more than one included survey and the median year of data collection was 2013. Most surveys were from Eastern Africa (51%). Only 10% of surveys had information on recent HIV infection (N_{surv}=6) and 12% had data on ART uptake and VLS (N_{surv}=7)(Figure 2).




Figure 1. Flowchart for survey inclusion/exclusion for each type of analysis: recent HIV infection, HIV testing, antiretroviral (ART) uptake and viral load suppression (VLS). We did not use 7 surveys with data on intimate partner violence (IPV) since information on past year physical IPV were not collected (N_{surv}=3) or information about HIV and intimate partner violence was gathered from different subgroups of women (N_{surv}=2) (i.e., HIV questions in the DHS were asked to women in households which were selected for the men's survey). We removed two surveys (Côte d'Ivoire PHIA 2017 and Cameroon PHIA 2017) where over 95% of past year IPV data were missing. (AIS=AIDS Indicator Survey; DHS=Demographic and Health Survey; Excl.=excluded; IPV=intimate partner violence; PHIA=Population-based HIV Impact Assessment Survey; SABSSM=South African National HIV Prevalence, Incidence, Behaviour and Communication Survey.)




Figure 2. Surveys with questions on HIV and intimate partner violence (IPV), by country and year, 2000-2020. Points represent population-based surveys conducted in sub-Saharan Africa from 2000-2020 and asking about HIV testing and intimate partner violence (IPV). Circles represent survey types. Different shapes indicate the type of analyses the surveys were included in a) only HIV testing b) HIV testing, antiretroviral (ART) uptake and viral load suppression (VLS), c) testing, ART uptake and VLS, and recent HIV infection. (AIS=AIDS Indicator Survey; ART=antiretroviral treatment; DHS=Demographic and Health Survey; Inc=HIV incidence (recent HIV infection); PHIA=Population-based HIV Impact Assessment Survey; SABSSM=South African National HIV Prevalence, Incidence, Behaviour and Communication Survey; VLS=viral load suppression.)

Study population

Overall, over one fifth (21%) of all ever-partnered women had experienced physical and/or sexual IPV in the past year and 29% in their lifetime. Central Africa had the highest prevalence of past year physical and/or sexual (29%) IPV, followed by Eastern Africa (23%) (Supplement 3; Table S6). Women who had experienced past year physical and/or sexual IPV were younger than those who had not, across the pooled surveys included in all the analyses (Supplement 4; Table S7-S10). Among women not living with HIV, close to half of those reporting IPV in the past year had only primary education, compared to 36% of those who did not report IPV (Supplement 4; Table S7). Most women living with HIV, irrespective of reporting IPV, had secondary education (Supplement 4; Table S8-S10).

Recent HIV infection

Among the six surveys with information on recent infections, a total of 45 women had recently acquired HIV (Table 1). Women not living with HIV who had not experienced past year physical and/or sexual IPV had 0·5%-point higher proportion of recent HIV infections compared to those who had. The crude PR for recent HIV infections is 3·50 (95%CI: 1·63-7·51, N_{surv}=6; Table 2). Adjusting for potential confounders, women who had experienced past year IPV were 3·22 times more likely (95%CI: 1·51-6·85, N_{surv}=6) to have a recent HIV infection than those who had not experienced IPV. (Table 2)

As a robustness check, we examined the HIV status of the cohabiting partners, partners' age discrepancy, partner education, partner alcohol consumption, and condom use at women's last sex as potential confounders in the six surveys included in the recent HIV infection analysis (Supplement 5; Table S11-S14). Partner age discrepancy and partner alcohol consumption varied between women having experienced past year IPV and those who had not; however the effect estimates are robust to confounding by these variables.

Table 1. Unweighted proportion of women and the number of analyzed surveys with each outcome of interest: recent HIV infection, lifetime HIV testing, past year HIV testing, antiretroviral therapy (ART) uptake and viral load suppression (VLS).

Outcome [‡]	Past year physical and/or sexual IPV			Lifetime physical IPV			Lif	Lifetime sexual IPV			Lifetime physical and/or sexual IPV		
	Surveys (N)	Yes	No	Surveys (N)	Yes	No	Surveys (N)	Yes	No	Surveys (N)	Yes	No	
Recent HIV	infection, n	(%)											
Yes No	6	8 (0.7%) 1,150	37 (0.2%) 18,740	1	2 (0.5%) 425	2 (0.1%) 2,044	1	0 (0%) 85	4 (0.2%) 2,384	1	2 (0.5%) 438	2 (0.1%) 2,031	
		(99.3%)	(99.8%)		(99.5%)	(99.9%)		(100%)	(99.8%)		(99.5%)	(99.9%)	
Lifetime HI	V testing, n		(((,	()		()	(
Yes	57	31,023 (52.5%)	113,384 (52.4%)	52	39,531 (53.8%)	83,757 (46.2%)	52	15,663 (55.2%)	107,624 (47.6%)	52	43,802 (54.0%)	79,483 (45.8%)	
No		28,101 (47.5%)	102,976 (47.6%)		33,908 (46.2%)	97,446 (53.8%)		12,704 (44.8%)	118,614 (52.4%)		37,347 (46.0%)	93,986 (54.2%)	
Past year HI													
Yes No	57	16,392 (27.8%) 42,601 (72.2%)	57,996 (26.9%) 157,969 (73.1%)	52	20,292 (27.7%) 52,993 (72.3%)	43,451 (24.0%) 137,456 (76.0%)	52	8,240 (29.1) 20,080 (70.9%)	55,506 (24.6) 170,329 (75.4%)	52	22,555 (27.9%) 58,429 (72.1%)	41,189 (23.8%) 131,995 (76.2%)	
ART uptake	e, n (%)	(, = : = :)	(, 2 : 2 :)		(, = , = ,	(, 51511)		(, , , , , ,	(, , , , , , , , , , , , , , , , , , ,		(, = : = :)	(, === : -)	
Yes	7	416 (64.2%)	3,717 (71.3%)	2	388 (64.8%)	675 (60.5%)	2	68 (66.7%)	996 (61.7%)	2	402 (64.9%)	661 (60.3%)	
No		232 (35.8%)	1,498 (28.7%)		211 (35.2%)	441 (39.5%)		34 (33.3%)	618 (38.3%)		217 (35.1%)	435 (39.7%)	
VLS, n (%)													
Yes	7	375 (56.7%)	3,506 (67.3%)	2	348 (57.0%)	645 (57.3%)	2	60 (60.6%)	934 (57.0%)	2	362 (57.4%)	631 (57.1%)	
No	. 14	286 (43.3%)	1,700 (32.7%)	C	262 (43.0%)	481 (42.7%)		39 (39.4%)	704 (43.0%)		269 (42.6%)	474 (42.9%)	

ART=antiretroviral therapy; IPV=intimate partner violence; Surv.=survey; VLS=viral load suppression.

‡Denominators for these proportions are the total number of women with or without each of the exposures of interest: past year physical and/or sexual IPV, lifetime physical IPV, lifetime physical and/or sexual IPV.

Table 2. Crude and adjusted prevalence ratios of HIV recent infection among women experiencing past-year physical and/or sexual intimate partner violence (IPV) compared to women not experiencing this type of IPV.

Exposures	N_{surv}	Ni	Crude PR (95% CI)	Adjusted PR [‡] (95% CI)			
Primary exposure of interest§							
Past year physical and/or sexual IPV	6	19,179	3.50 (1.63, 7.51)	3.22 (1.51, 6.85)			
Secondary exposure of interest							
Frequency of past year physical and/or sexual IPV [¥]							
Never	6	19,178	Referent	Referent			
Sometimes			3.23 (1.36, 7.62)	2.96 (1.27, 6.89)			
Often			4.75 (1.15, 19.7)	4.50 (0.97, 20.85)			

95%CI=95% confidence intervals; IPV=intimate partner violence; N_{surv}=number of surveys; N_i=number of individual observations without any missing data for intimate partner violence (IPV), the outcome and the covariates included in the model; PR=prevalence ratio.

- ‡ Adjusted for: age (continuous), age at sexual debut (continuous), residence type (rural/urban), women's current marital status (married/unmarried), women's education (none, primary, secondary, higher), and survey identifier.
- § 5/6 surveys included in the HIV acquisition analysis were PHIA (Population-based HIV Impact Assessment Survey), which does not collect data on our secondary exposures of interest: lifetime physical IPV, lifetime sexual IPV, lifetime physical and/or sexual IPV.
 - ¥ In PHIA surveys (5/6) the frequency of past-year intimate partner violence (IPV) pertains to only recent physical, not sexual IPV. Furthermore, this question asks about perpetration of violence by "someone" which we assume to be an intimate partner only when the woman has also reported experiencing IPV. The referent category for the frequency of past year physical and/or sexual IPV are women who did not experience any past year physical and/or sexual intimate partner violence (IPV).

HIV testing

Self-reports of HIV testing in the past year were similar between women who had experienced IPV and those who had not. About a quarter of women in both groups had been tested in the past year (28% and 27% among those who experienced IPV and those who had not, respectively) and nearly half of all women (regardless of experience of IPV in the past year) ever tested for HIV (Table 1).

The crude PR of past year physical and/or sexual IPV on recent HIV testing was 0.98 (95%CI: 0.97-0.99). Adjusting for potential confounders, experience of past year IPV had no effect on recent HIV testing (aPR=0.99, 95%CI: 0.98-1.01, $N_{surv}=57$). Women experiencing lifetime physical and/or sexual IPV were 2% more likely to report lifetime testing (aPR=1.02, 95%CI: 1.02-1.03, $N_{surv}=52$) (Table 3).

Similar results were obtained in sensitivity analyses where we excluded women who reported testing at ANC. Experience of lifetime physical and/or sexual IPV was associated with a small increase in lifetime HIV testing among women who tested outside of the ANC (aPR=1·04, 95%CI: 1·03-1·05, N_{surv}=52; Supplement 6; Table S15).

Table 3. Crude and adjusted prevalence ratios of lifetime and past year HIV testing among women experiencing different intimate partner violence (IPV) categories compared to women not experiencing a specific type of IPV.

Outcomes	Exposures	N_{surv}	Ni	Crude PR (95% CI)	Adjusted PR [‡] (95% CI)
Past year H	IV testing			·	
Primary ex	posure of interest				
•	Past year physical and/or sexual IPV	57	274,506	0.98(0.97, 0.99)	0.99 (0.98, 1.01)
Secondary	exposures of interest				
·	Lifetime physical IPV	52	254,041	0.99 (0.97, 1.00)	1.00 (0.99, 1.01)
	Lifetime sexual IPV	52	254,005	0.99 (0.98, 1.01)	0.99 (0.97, 1.00)
	Lifetime physical and/or sexual IPV	52	254,017	0.99 (0.98, 1.00)	0.99 (0.98, 1.01)
	Severe lifetime physical and/or sexual IPV [†]	52	253,977	0.97 (0.96, 0.99)	0.98 (0.97, 0.99)
	Frequency of past-year physical and/or sexual IPV [¥]		·	, ,	,
	Never	57	274,505	Referent	Referent
	Sometimes			0.99 (0.98, 1.00)	0.99 (0.98, 1.01)
	Often			0.95 (0.92, 0.97)	0.99 (0.96, 1.01)
Lifetime HI	V testing				
.,	exposures of interest				
	Lifetime physical IPV	52	254,464	1.01 (1.00, 1.02)	1.02 (1.02, 1.03)
	Lifetime sexual IPV	52	254,428	1.00 (0.99, 1.01)	1.01 (1.00, 1.01)
	Lifetime physical and/or sexual IPV	52	254,440	1.01 (1.01, 1.02)	1.02 (1.02, 1.03)
	Severe lifetime physical and/or sexual IPV§	52	254,399	1.00 (0.99, 1.01)	1.01 (1.00, 1.02)

95%CI=95% confidence intervals; IPV=intimate partner violence; N_{surv}=number of surveys; N_i=number of individual observations without any missing data for intimate partner violence (IPV), the outcome and the covariates included in the model; PR=prevalence ratio.

‡ Adjusted for: age (continuous), residence type (rural/urban), women's current marital status (married/unmarried), women's education (none, primary, secondary, higher), and survey identifier.

¥ In PHIA surveys (5/6) the frequency of past-year intimate partner violence (IPV) pertains to only recent physical, not sexual IPV. Furthermore, this question asks about perpetration of violence by "someone" which we assume to be an intimate partner only when the woman has also reported experiencing IPV. The referent category for the frequency of past year physical and/or sexual IPV are women who did not experience any past year physical and/or sexual intimate partner violence (IPV).

† Referent category includes women experiencing non-severe lifetime IPV and no lifetime IPV.

Antiretroviral therapy uptake

 WLHIV who had reported past year physical and/or sexual IPV compared to those who had not had $7\cdot1\%$ -point lower ART uptake (Table 1). The crude PR for ART uptake was $0\cdot90$ (95%CI: $0\cdot85-0\cdot96$, $N_{surv}=7$). After adjustments, women who had reported past year IPV were 4% less likely to be on ART, compared to those who had not (aPR= $0\cdot96$, 95%CI: $0\cdot90-1\cdot03$, $N_{surv}=7$), but we cannot rule out the absence of an effect. Severe lifetime IPV slightly increased the strength of the association with poor ART uptake (aPR= $0\cdot94$, 95%CI: $0\cdot84-1\cdot05$, $N_{surv}=2$), though this analysis was restricted to two surveys with information which decreased the precision of the estimate (Table 4).

Table 4. Crude and adjusted prevalence ratios of antiretroviral (ART) uptake among women living with HIV (WLHIV) experiencing different intimate partner violence (IPV) categories compared to WLHIV not experiencing a specific type of IPV

Exposures	N_{surv}	N_i §	Crude PR (95% CI)	Adjusted PR [‡] (95% CI)
Primary exposure of interest				
Past year physical and/or sexual IPV	7	5,629	0.90 (0.85, 0.96)	0.96 (0.9, 1.03)
Secondary exposures of interest				
Lifetime physical IPV	2	1,569	1.06 (0.98, 1.14)	1.00 (0.93, 1.08)
Lifetime sexual IPV	2	1,570	1.08 (0.94, 1.24)	1.05 (0.91, 1.21)
Lifetime physical and/or sexual IPV	2	1,569	1.06 (0.98, 1.14)	1.01 (0.94, 1.09)
Severe lifetime physical and/or sexual IPV [†]	2	1,568	0.93 (0.83, 1.04)	0.94 (0.84, 1.05)
Frequency of past-year physical and/or sexual IPV [¥]			,	, ,
Never	7	5,629	Referent	Referent
Sometimes			0.91 (0.86, 0.97)	0.96 (0.90, 1.03)
Often			0.84 (0.71, 0.99)	0.97 (0.82, 1.16)

- 95%CI=95% confidence intervals; ART=antiretroviral treatment; IPV=intimate partner violence; N_{surv}=number of surveys; N_i=number of individual observations without any missing data for intimate partner violence (IPV), the outcome and the covariates included in the model; PR=prevalence ratio; WLHIV=women living with HIV.
- \$\frac{328}{329}\$ \$\pm\$ Adjusted for: age (continuous), residence type (rural/urban), women's current marital status (married/unmarried), women's education (none, primary, secondary, higher), and survey identifier.
 - ¥ In PHIA surveys (5/6) the frequency of past-year intimate partner violence (IPV) pertains to only recent physical, not sexual IPV. Furthermore, this question asks about perpetration of violence by "someone" which we assume to be an intimate partner only when the woman has also reported experiencing IPV. The referent category for the frequency of past year physical and/or sexual IPV are women who did not experience any past year physical and/or sexual intimate partner violence (IPV).
 - \S 0.7% of women were removed because they had a recent HIV infection and did not have time to be diagnosed and linked to treatment.
 - † Referent category includes women experiencing non-severe lifetime IPV and no lifetime IPV.

Viral load suppression

WLHIV who had experienced past year physical and/or sexual IPV compared to those who had not had $10\cdot6\%$ -point lower VLS (Table 1). The crude PR for VLS was $0\cdot85$ (95%CI: $0\cdot79-0\cdot91$, $N_{surv}=7$). After adjusting for confounders, women who had experienced past year IPV were 9% less likely to be virally suppressed, compared to those who had not (aPR= $0\cdot91$, 95%CI: $0\cdot85-0\cdot98$, $N_{surv}=7$; Table 5). Lifetime physical and/or sexual IPV had an adverse effect on VLS as well, though the confidence interval includes the null (aPR= $0\cdot94$, 95%CI: $0\cdot86-1\cdot02$, $N_{surv}=2$).

We further looked at the effect of IPV on VLS, restricting to women on ART. The effect size estimate between past year IPV and VLS among WLHIV on ART was smaller. WLHIV on ART who had experienced past year IPV were 6% less likely to have VLS compared to women who had not (aPR=0.94, 95%CI: 0.90-0.99, N_{surv} =7; Supplement 6; Table S16). Higher frequency of IPV in the past year was associated with a 14% reduction in the likelihood of VLS although the estimates were imprecise (aPR=0.86, 95%CI: 0.72-1.02, N_{surv} =7).

Table 5. Crude and adjusted prevalence ratios of viral load suppression (VLS) among women living with HIV (WLHIV) experiencing different intimate partner violence (IPV) categories compared to WLHIV not experiencing a specific type of IPV.

Exposures	N_{surv}	N_i §	Crude PR (95% CI)	Adjusted PR [‡] (95% CI)
Primary exposure of interest				
Past year physical and/or sexual IPV	7	5,627	0.85(0.79, 0.91)	0.91 (0.85, 0.98)
Secondary exposures of interest				
Lifetime physical IPV	2	1,583	0.99 (0.91, 1.07)	0.93 (0.85, 1.01)
Lifetime sexual IPV	2	1,584	1.08 (0.91, 1.27)	1.04 (0.88, 1.23)
Lifetime physical and/or sexual IPV	2	1,583	1.00 (0.92, 1.08)	0.94 (0.86, 1.02)
Severe lifetime physical and/or sexual IPV [†]	2	1,582	0.99 (0.88, 1.12)	1.01 (0.90, 1.14)
Frequency of past-year physical and/or sexual IPV^{Σ}				
Never	7	5,627	Referent	Referent
Sometimes			0.86(0.8, 0.93)	0.91 (0.84, 0.98)
Often			0.74 (0.61, 0.91)	0.89 (0.73, 1.09)

95%CI=95% confidence intervals; IPV=intimate partner violence; PR=prevalence ratio; N_{surv} =number of surveys; N_i =number of individual observations without any missing data for intimate partner violence (IPV), the outcome and the covariates included in the model; VLS=viral load suppression; WLHIV=women living with HIV.

‡ Adjusted for: age (continuous), residence type (rural/urban), women's current marital status (married/unmarried), women's education (none, primary, secondary, higher), and survey identifier.

¥ In PHIA surveys (5/6) the frequency of past-year intimate partner violence (IPV) pertains to only recent physical, not sexual IPV. Furthermore, this question asks about perpetration of violence by "someone" which we assume to be an intimate partner only when the woman has also reported experiencing IPV. The referent category for the frequency of past year physical and/or sexual IPV are women who did not experience any past year physical and/or sexual intimate partner violence (IPV).

 \S 0.7% of women were removed because they had a recent HIV infection and did not have time to be diagnosed and linked to treatment.

[†] Referent category includes women experiencing non-severe lifetime IPV and no lifetime IPV.

Discussion

IPV is a human right violation, a global health concern, and our study shows that it could contribute to HIV epidemics. In our pooled analysis of population-based surveys, women who had experienced physical and/or sexual IPV over the past year were over 3 times more likely to have acquired a recent HIV infection compared to those who had not. Although we did not find evidence of the impact of past year IPV on HIV testing, WLHIV who experienced physical and/or sexual IPV in the past year were 9% less likely to be virally suppressed. In line with the *United Nations 2021 Political Declaration* to end gender inequalities perpetuating the HIV/AIDS epidemic, the available evidence^{9,10} suggest that elimination of IPV could be partly responsible for reductions in new HIV infections and improvements viral load suppresion.⁵²

In sub-Saharan Africa, the links between IPV and HIV have previously been studied using HIV prevalence as the outcome. 5-8,49 Such study designs make it difficult to disentangle temporality between experience of IPV and HIV acquisition. We leveraged recent infection assays that were recently deployed in large population-based surveys such as PHIA, as a proxy for HIV incidence. Our results align with previous cohort studies, but our effect size estimates are larger. 6,9,10 Longitudinal studies in South Africa and Uganda show that women who had been subjected to physical or sexual IPV had 1.5 times the HIV incidence compared to those who had not. 9,10 Larger effect size in our study may be attributable to the exposure-driven selection bias in cohort studies and/or generalizability of effect size estimates from randomized controlled trials and cohort studies. 9,10

Pathways through which IPV can affect HIV acquisition are complex and multifaceted. While the most direct path is through sexual assault, a growing body of evidence suggests that at the population level, structural factors surrounding IPV play a larger role. 53,54 Men who perpetrate IPV may be more likely to have a high number of concurrent sexual partners, use condoms inconsistently, and use substances, and thus are more likely to be living with HIV which in turn could lead to HIV transmission to their partners. 54-58 Crude, descriptive evidence from our study suggests that the proportion of partners who are living with HIV and condom use at last sex are comparable between women experiencing and not experiencing IPV in the past year. Partner age discrepancy and partner alcohol consumption varied between women who had experienced IPV and those who had not, but the effect estimates remained robust to confounding by these covariates.

Knowledge of HIV status among WLHIV –the first step in the cascade– can be a key bottleneck in the HIV care cascade. In our study, IPV did not impact HIV testing, even after excluding women who had tested at ANC (as HIV testing at ANC achieved high coverage). Overall, evidence regarding the effect of IPV on HIV testing is mixed. Some studies suggested lower rates of HIV testing due to a fear of violent reaction from one's partner if the HIV test comes back positive. Occasional Most studies from low-and middle-income countries found no relationship, or even a positive relationship between IPV and HIV testing, which might be due to a higher self-perceived risk among the IPV survivor. Some studies from low-and middle-income countries found no relationship, or even a positive relationship between IPV and HIV testing, which might be due to a higher self-perceived risk among the IPV survivor. Some studies in our study, where lifetime experience of physical and/or sexual IPV is associated with a small increase in lifetime HIV testing, which might speak to the cumulative nature of lifetime experience of IPV and associated high self-perceived risk. Null results could also be reflective of the unprecedented scale-up of HIV-testing in sub-Saharan Africa in the past decade.

Our results suggest that women who had experienced past year IPV were less likely to be on ART, compared to those who had not, though our results were not conclusive. Most existing studies conducted in low- and middle-income countries look at the effects of IPV on ART adherence. Those that assessed current ART use did not uncover relationships between the two, which aligns with our results. However, we found that IPV was adversely associated with VLS, even among women who are on ART, which implies that ART adherence could be the bottleneck in WLHIV's success in the HIV care cascade. Pathways through which IPV affects ART uptake and adherence are complex. Some women might hide their HIV status due to fear of their partner's reaction, making it difficult to enroll in HIV care and adhere to treatment. Head of IPV could restrict women's access to healthcare through male control of resources, and freedoms of mobility and decision-making. Head of the partner of the partner

Our results should be interpreted considering the study's limitations. First, all surveys depend on self-reports of IPV and might be subject to under-reporting due to their sensitive nature. 70 However, the surveys used appropriate measures to ensure confidentiality. HIV testing was also self-reported, though evidence shows that self-reported HIV-testing histories are generally robust. 71 Second, some of the included surveys slightly differed in terms of their question wordings on IPV (e.g., frequency of past-year violence was a continuous variable and had to be categorized). Nevertheless, questions were all acts-based and modified from the Conflict Tactics Scales.³⁸ Third, we did not include emotional violence in the definition of intimate partner violence, due to a lack of consensus on how to define, conceptualize, and measure this construct cross-culturally. 72 Fourth, few surveys had information on recent HIV infection, ART uptake and VLS as compared to HIV testing histories. However, pooling all data sources allowed us to improve the precision of our estimates. Fifth, we used cross-sectional survey data and reverse causality remains a possibility. This limitation was alleviated, however, by restricting our main exposure to recent IPV, examining recent HIV infection, and ART uptake and VLS at the time of the interview. Sixth, non-response could threaten the validity of our results, leading to selection bias and potential underestimation of the effect size measure (Supplement 2). Finally, our descriptive analyses of male partner characteristics were based on a small sample, and we cannot rule out residual confounding.

Strengths of our study include a comprehensive analysis of available population-based surveys with information on IPV and HIV. Second, our large sample size allowed us to estimate the adjusted prevalence ratios for the relationships between IPV, recent HIV infection and each stage of the HIV treatment and care cascade. Finally, we conducted several sensitivity analyses to assess the robustness of our findings.

Our results have important policy implications for HIV prevention and care delivery in high HIV burden settings. At a service delivery-level, healthcare provider training should include IPV-sensitive topics such as probing women in a nonjudgmental way to safely disclose their experience of IPV. This could identify women at higher risk of disengagement from care who can subsequently be linked to women-centric HIV services. Emergence of novel, patient-focused HIV service delivery platforms, also known as "differentiated service delivery" models could incorporate women-only community adherence groups or safe community-based medication pick-up points.⁷³

At a macro level, harmful gender norms remain worldwide such that a large proportion of youth still agree that a husband is sometimes justified in beating his wife.³² Systemic work is required to eradicate such attitudes and to mitigate their impact on HIV outcomes among women, such as HIV educational campaigns for youth that have a strong gender equity component.⁷⁴ National legislative systems must provide frameworks for these structural changes. Although in 103 countries, criminal penalties exist for IPV, their implementation varies.³² Such laws must be better enacted and enforced as the national legal environments often deepen gender inequality and undermine national HIV responses.

In conclusion, IPV could have important adverse effects on HIV epidemics by contributing to HIV acquisition risks and decreasing VLS among WLHIV. Efforts to prevent intimate partner violence and violence against women more broadly should be included in HIV control programs and indicators of IPV collected and monitored as part of HIV surveillance. The IPV/HIV syndemic needs recognition by governments and communities if we are to eliminate IPV and reduce HIV risk among women.

Contributions

457

458

459

460

461 462

463

464

465

466

467

468

469

470

471

477

484

491

492

493

- SK and MMG conceived of the study. SK performed the analyses. MMG and DP contributed to
- 473 the study methods and reviewing and editing the manuscript. SK wrote the initial draft of the
- 474 manuscript. DP, MCB, SD, JWE, FM, LS, LSC, HS, RW and MMG helped interpret the results
- and provided valuable feedback on the policy implications of the study. All authors contributed
- 476 to and approved the final manuscript.

Acknowledgments

- We are grateful and indebted to the survey teams who made their data publicly available and to
- all survey participants.

480 Funding

- This study is funded by the Canadian Institutes of Health Research. MMG's research program is
- 482 funded by a Canada Research Chair (Tier 2) in Population Health Modeling. SK received a Max
- 483 E. Binz Fellowship from McGill University.

Data sharing

- Data used in the study are publicly available for investigators who submit an abstract and a data
- analysis plan as part of *Demographic and Health Surveys* (DHS), *AIDS Indicator Surveys* (AIS)
- 487 (https://dhsprogram.com/Data/), Population-based HIV Impact Assessment (PHIA) (https://phia-
- data.icap.columbia.edu/datasets) and South Africa National HIV Prevalence, Incidence, Behavior
- and Communication Survey (SABSSM) (http://datacuration.hsrc.ac.za/search/browse/alpha/S).
- 490 Analysis code and clean data that support the findings of the study are available upon request.

Declaration of interests

MM-G reports an investigator-sponsored research grant from Gilead Sciences Inc., and contractual arrangements from the *Institut national de santé publique du Québec* (INSPQ), the

Institut d'excellence en santé et services sociaux (INESSS), the World Health Organization, and the Joint United Nations Programme on HIV/AIDS (UNAIDS), all outside of the submitted work.

References

- 1. Garcia-Moreno C. Violence Against Women: International Perspectives. *American Journal of Preventive Medicine* 2000; **19**(4): 330-3.
- 501 2. Garcia-Moreno C, Heise L, Jansen HA, Ellsberg M, Watts C. Public health. Violence 302 against women. *Science* 2005; **310**(5752): 1282-3.
- 3. Garcia-Moreno C, Watts C. Violence against women: its importance for HIV/AIDS. *AIDS* 2000; **14 Suppl 3**: S253-65.
- 505 4. Martin SL, Curtis S. Gender-based violence and HIV/AIDS: recognising links and acting 506 on evidence. *Lancet* 2004; **363**(9419): 1410-1.
- 507 5. Kouyoumdjian FG, Findlay N, Schwandt M, Calzavara LM. A systematic review of the relationships between intimate partner violence and HIV/AIDS. *PLoS One* 2013; **8**(11): e81044.
- 509 6. Li Y, Marshall CM, Rees HC, Nunez A, Ezeanolue EE, Ehiri JE. Intimate partner
- violence and HIV infection among women: a systematic review and meta-analysis. *J Int AIDS* Soc 2014; **17**: 18845.
- 512 7. Campbell JC, Baty ML, Ghandour RM, Stockman JK, Francisco L, Wagman J. The
- intersection of intimate partner violence against women and HIV/AIDS: a review. *Int J Inj Contr Saf Promot* 2008; **15**(4): 221-31.
- 515 8. Durevall D, Lindskog A. Intimate partner violence and HIV in ten sub-Saharan African
- countries: what do the Demographic and Health Surveys tell us? *Lancet Glob Health* 2015; **3**(1): e34-43.
- 518 9. Kouyoumdjian FG, Calzavara LM, Bondy SJ, et al. Risk factors for intimate partner
- violence in women in the Rakai Community Cohort Study, Uganda, from 2000 to 2009. *BMC Public Health* 2013; **13**(566).
- 521 10. Jewkes RK, Dunkle K, Nduna M, Shai N. Intimate partner violence, relationship power
- 522 inequity, and incidence of HIV infection in young women in South Africa: a cohort study. *Lancet* 2010; **376**(9734): 41-8.
- 524 11. Zablotska IB, Gray RH, Koenig MA, et al. Alcohol use, intimate partner violence, sexual
- 525 coercion and HIV among women aged 15-24 in Rakai, Uganda. *AIDS Behav* 2009; **13**(2): 225-526 33.
- 527 12. Were E, Curran K, Delany-Moretlwe S, et al. A prospective study of frequency and
- 528 correlates of intimate partner violence among African heterosexual HIV serodiscordant couples. 529 *AIDS* 2011; **25**(16): 2009-18.
- 13. Hatcher AM, Smout EM, Turan JM, Christofides N, Stockl H. Intimate partner violence
- and engagement in HIV care and treatment among women: a systematic review and meta-
- 532 analysis. AIDS 2015; **29**(16): 2183-94.
- 533 14. Leddy AM, Weiss E, Yam E, Pulerwitz J. Gender-based violence and engagement in
- biomedical HIV prevention, care and treatment: a scoping review. BMC Public Health 2019;
- 535 **19**(1): 897.
- 15. Nelson KA, Ferrance JL, Masho SW. Intimate partner violence, consenting to HIV testing
- and HIV status among Zambian women. Int J STD AIDS 2016; 27(10): 832-9.
- 538 16. Nikolova SP, Small E, Mengo C. Components of resilience in gender: a comparative
- analysis of HIV outcomes in Kenya. *Int J STD AIDS* 2015; **26**(7): 483-95.
- 540 17. Lyons CE, Grosso A, Drame FM, et al. Physical and Sexual Violence Affecting Female
- Sex Workers in Abidjan, Cote d'Ivoire: Prevalence, and the Relationship with the Work
- 542 Environment, HIV, and Access to Health Services. *J Acquir Immune Defic Syndr* 2017; **75**(1): 9-543 17.
- 544 18. Conroy A, Leddy A, Johnson M, Ngubane T, van Rooyen H, Darbes L. 'I told her this is
- your life': relationship dynamics, partner support and adherence to antiretroviral therapy among
- 546 South African couples. *Cult Health* Sex 2017; **19**(11): 1239-53.

- 547 19. Kiarie JN, Farguhar C, Richardson BA, et al. Domestic violence and prevention of
- 548 mother-to-child transmission of HIV-1. *AIDS* 2006; **20**(13): 1763-9.
- 549 20. Mohammed BH, Johnston JM, Harwell JI, Yi H, Tsang KW, Haidar JA. Intimate partner
- violence and utilization of maternal health care services in Addis Ababa, Ethiopia. *BMC Health*
- 551 Serv Res 2017; **17**(1): 178.
- 552 21. Turan JM, Bukusi EA, Onono M, Holzemer WL, Miller S, Cohen CR. HIV/AIDS stigma
- and refusal of HIV testing among pregnant women in rural Kenya: results from the MAMAS
- 554 Study. AIDS Behav 2011; **15**(6): 1111-20.
- 555 22. Kidman R, Violari A. Dating Violence Against HIV-Infected Youth in South Africa:
- 556 Associations With Sexual Risk Behavior, Medication Adherence, and Mental Health. J Acquir
- 557 Immune Defic Syndr 2018: **77**(1): 64-71.
- 558 23. Hampanda K. Intimate Partner Violence Against HIV-Positive Women is Associated with
- 559 Sub-Optimal Infant Feeding Practices in Lusaka, Zambia. *Matern Child Health J* 2016; **20**(12):
- 560 2599-606.
- 561 24. Biomndo BC, Bergmann A, Lahmann N, Atwoli L. Intimate partner violence is a barrier to
- antiretroviral therapy adherence among HIV-positive women: Evidence from government
- 563 facilities in Kenya. *PLoS One* 2021; **16**(4): e0249813.
- 564 25. Hatcher AM, Stöckl H, Christofides N, et al. Mechanisms linking intimate partner
- violence and prevention of mother-to-child transmission of HIV: A qualitative study in South
- 566 Africa. Soc Sci Med 2016; **168**: 130-9.
- 567 26. Merrill KG, Campbell JC, Decker MR, et al. Past-Year Violence Victimization is
- Associated with Viral Load Failure Among HIV-Positive Adolescents and Young Adults. *AIDS*
- 569 Behav 2021; **25**(5): 1373-83.
- 570 27. Hatcher AM, Brittain K, Phillips TK, Zerbe A, Abrams EJ, Myer L. Longitudinal
- association between intimate partner violence and viral suppression during pregnancy and
- 572 postpartum in South African women. *AIDS* 2021; **35**(5): 791-9.
- 573 28. UNAIDS. UNAIDS Data 2021, 2021.
- 574 29. UNAIDS. Global HIV Statistics: Fact Sheet, 2021.
- 575 30. UNAIDS. Fast-Track: Ending the AIDS Epidemic by 2030, 2014.
- 576 31. Sardinha L M-GM, Stockl H, Meyer S, Garcia-Moreno C. Global, regional and national
- 577 prevalence estimates of physical and/or sexual intimate partner violence against women, 2018.
- 578 Lancet 2022; **399**(10327): P803-13.
- 579 32. UNAIDS. Global AIDS update: Confronting inequalities, 2021.
- 580 33. Schaefer R, Gregson S, Fearon E, Hensen B, Hallett TB, Hargreaves JR. HIV
- prevention cascades: A unifying framework to replicate the successes of treatment cascades.
- 582 Lancet HIV 2019; **6**(1): e60-e6.
- 583 34. Hampanda KM. Intimate partner violence and HIV-positive women's non-adherence to
- antiretroviral medication for the purpose of prevention of mother-to-child transmission in Lusaka,
- 585 Zambia. Soc Sci Med 2016; **153**: 123-30.
- 586 35. Wechsberg WM, van der Horst C, Ndirangu J, et al. Seek, test, treat: substance-using
- women in the HIV treatment cascade in South Africa. Addict Sci Clin Pract 2017; 12(1): 12.
- 588 36. Stockl H, Sardinha L, Maheu-Giroux M, Meyer SR, Garcia-Moreno C. Physical, sexual
- and psychological intimate partner violence and non-partner sexual violence against women
- and girls: a systematic review protocol for producing global, regional and country estimates.
- 591 BMJ Open 2021; **11**(8): e045574.
- 592 37. Giguere K, Eaton JW, Marsh K, et al. Trends in knowledge of HIV status and efficiency
- of HIV testing services in sub-Saharan Africa, 2000-20: a modelling study using survey and HIV
- 594 testing programme data. *Lancet HIV* 2021; **8**(5): e284-e93.
- 595 38. Straus M. The Revised Conflict Tactics Scale. *Journal of Family Issues* 1996; **17**(3):
- 596 286-316.
- 597 39. Kishor S. Domestic violence measurement in the demographic and health surveys:

- 598 The history and the challenges. Geneva, Switzerland, 2005.
- 599 40. Maheu-Giroux M SL, Stöckl H, Meyer S, Godin A, Alexander M, García-Moreno C.
- [Preprint] A framework to model global, regional, and national estimates of intimate partner violence. 2022.
- 41. Laeyendecker O, Gray RH, Grabowski MK, et al. Validation of the Limiting Antigen
- Avidity Assay to Estimate Level and Trends in HIV Incidence in an A/D Epidemic in Rakai,
- 604 Uganda. AIDS Res Hum Retroviruses 2019; **35**(4): 364-7.
- 605 42. WHO. HIV Incidence Meaasurement and Data Use. Boston, 2018.
- 606 43. Mitchell KM, Maheu-Giroux M, Dimitrov D, et al. How can progress towards Ending the
- HIV Epidemic in the United States be monitored? *Clin Infect Dis* 2021.
- Hallett TB, Lewis JJ, Lopman BA, et al. Age at first sex and HIV infection in rural
- 609 Zimbabwe. *Stud Fam Plann* 2007; **38**(1): 1-10.
- 610 45. Kouyoumdjian F. Intimate Partner Violence as a Risk Factor for Incident HIV Infection in
- Women in Rakai, Uganda. Toronto: University of Toronto; 2014.
- 612 46. Shamu S, Abrahams N, Temmerman M, Musekiwa A, Zarowsky C. A systematic review
- of African studies on intimate partner violence against pregnant women: prevalence and risk
- 614 factors. PLoS One 2011; **6**(3): e17591.
- 615 47. Auvert B, Buve A, Ferry B, et al. Ecological and individual level analysis of risk factors
- for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV
- 617 infection. AIDS 2001; **15**: S15-30.
- 618 48. Nabaggala MS, Reddy T, Manda S. Effects of rural-urban residence and education on
- intimate partner violence among women in Sub-Saharan Africa: a meta-analysis of health
- 620 survey data. BMC Womens Health 2021; **21**(1): 149.
- 49. Harling G, Msisha W, Subramanian SV. No association between HIV and intimate
- partner violence among women in 10 developing countries. *PLoS One* 2010; **5**(12): e14257.
- 623 50. Solon GH, S and Wooldridge J. [Working paper] What Are We Weighting For? In:
- Research NBoE, editor.; 2013.
- 625 51. Højsgaard S. Package 'geepack', 2022.
- 626 52. Wagman JA, Gray RH, Campbell JC, et al. Effectiveness of an integrated intimate
- partner violence and HIV prevention intervention in Rakai, Uganda: analysis of an intervention in
- an existing cluster randomised cohort. Lancet Glob Health 2015; 3(1): e23-33.
- 629 53. McLean I, Roberts SA, White C, Paul S. Female genital injuries resulting from
- consensual and non-consensual vaginal intercourse. Forensic Sci Int 2011; **204**(1-3): 27-33.
- 54. Dunkle KL, Decker MR. Gender-based violence and HIV: reviewing the evidence for
- 632 links and causal pathways in the general population and high-risk groups. Am J Reprod
- 633 *Immunol* 2013; **69**: 20-6.
- 55. Decker MR, Seage GR, 3rd, Hemenway D, et al. Intimate partner violence functions as
- both a risk marker and risk factor for women's HIV infection: findings from Indian husband-wife
- 636 dyads. *J Acquir Immune Defic Syndr* 2009; **51**(5): 593-600.
- 56. Jewkes R, Sikweyiya Y, Morrell R, Dunkle K. The relationship between intimate partner
- 638 violence, rape and HIV amongst South African men: a cross-sectional study. *PLoS One* 2011;
- 639 **6**(9): e24256.
- 57. Jewkes R, Dunkle K, Nduna M, et al. Factors associated with HIV sero-status in young
- 641 rural South African women: connections between intimate partner violence and HIV. Int J
- 642 Epidemiol 2006; **35**(6): 1461-8.
- 58. Silverman JG, McCauley HL, Decker MR, Miller E, Reed E, Raj A. Coercive forms of
- sexual risk and associated violence perpetrated by male partners of female adolescents.
- 645 Perspect Sex Reprod Health 2011; **43**(1): 60-5.
- 646 59. Pearlman DN, Averbach AR, Zierler S, Cranston K. Disparities in prenatal HIV testing:
- evidence for improving implementation of CDC screening guidelines. J Natl Med Assoc 2005;
- 648 **97**(7): 44S-51S.

- 649 60. Etudo O, Metheny N, Stephenson R, Kalokhe AS. Intimate partner violence is linked to
- less HIV testing uptake among high-risk, HIV-negative women in Atlanta. AIDS Care 2017;
- 651 **29**(8): 953-6.
- 652 61. Nasrullah M, Oraka E, Breiding MJ, Chavez PR. HIV testing and intimate partner
- violence among non-pregnant women in 15 US states/territories: findings from behavioral risk
- factor surveillance system survey data. AIDS Behav 2013; 17(7): 2521-7.
- 655 62. Satyanarayana VA, Chandra PS, Vaddiparti K, Benegal V, Cottler LB. Factors
- influencing consent to HIV testing among wives of heavy drinkers in an urban slum in India.
- 657 AIDS Care 2009; **21**(5): 615-21.
- 658 63. Raj A, Silverman JG, Amaro H. Abused women report greater male partner risk and
- gender-based risk for HIV: findings from a community-based study with Hispanic women. *AIDS Care* 2004; **16**(4): 519-29.
- 661 64. Sullivan KA, Messer LC, Quinlivan EB. Substance abuse, violence, and HIV/AIDS
- 662 (SAVA) syndemic effects on viral suppression among HIV positive women of color. *AIDS Patient* 663 *Care STDS* 2015; **29**: S42-8.
- 664 65. Espino SR, Fletcher J, Gonzalez M, Precht A, Xavier J, Matoff-Stepp S. Violence
- screening and viral load suppression among HIV-positive women of color. *AIDS Patient Care*
- 666 STDS 2015; **29**(1): S36-41.
- 667 66. Machtinger EL, Haberer JE, Wilson TC, Weiss DS. Recent trauma is associated with
- antiretroviral failure and HIV transmission risk behavior among HIV-positive women and female-
- 669 identified transgenders. *AIDS Behav* 2012; **16**(8): 2160-70.
- 670 67. Maman S, Mbwambo JK, Hogan NM, et al. HIV-positive women report more lifetime
- partner violence: findings from a voluntary counseling and testing clinic in Dar es Salaam,
- 672 Tanzania. Am J Public Health 2002; **92**(8): 1331-7.
- 673 68. Khan MN, Islam MM. Women's attitude towards wife-beating and its relationship with
- 674 reproductive healthcare seeking behavior: A countrywide population survey in Bangladesh.
- 675 PLoS One 2018; **13**(6): e0198833.
- 676 69. Daftary A, Padayatchi N, Padilla M. HIV testing and disclosure: a qualitative analysis of
- TB patients in South Africa. *AIDS Care* 2007; **19**(4): 572-7.
- 678 70. Ellsberg M, Heise L, Peña R, Agurto S, Winkvist A. Researching domestic violence
- against women: methodological and ethical considerations. Stud Fam Plann 2001; **32**(1): 1-16.
- 680 71. Xia Y, Milwid RM, Godin A, et al. Accuracy of self-reported HIV-testing history and
- awareness of HIV-positive status in four sub-Saharan African countries. *AIDS* 2021; **35**(3): 503-682 10.
- Heise L, Pallitto C, Garcia-Moreno C, Clark CJ. Measuring psychological abuse by
- intimate partners: Constructing a cross-cultural indicator for the Sustainable Development
- 685 Goals. SSM Popul Health 2019; 9: 100377.
- 686 73. Roy M, Bolton Moore C, Sikazwe I, Holmes CB. A Review of Differentiated Service
- Delivery for HIV Treatment: Effectiveness, Mechanisms, Targeting, and Scale. Curr HIV/AIDS
- 688 Rep 2019; **16**(4): 324-34.
- 689 74. Sharma V, Leight J, Verani F, Tewolde S, Deyessa N. Effectiveness of a culturally
- appropriate intervention to prevent intimate partner violence and HIV transmission among men,
- women, and couples in rural Ethiopia: Findings from a cluster-randomized controlled trial. *PLoS*
- 692 *Med* 2020; **17**(8): e1003274.

694